NeuroPace NAUTILUS study meets safety endpoint; primary efficacy miss but significant in subgroup

NeuroPace Inc

Primary safety endpoint met: low rate of serious adverse events related to device/implant procedure.
Primary efficacy endpoint (time to second GTC seizure) not statistically significant in overall population.
Statistically significant response in subgroup with lower baseline GTC seizure frequency, representing majority of participants.
Secondary metrics (median seizure reduction, responder rates, seizure-free days) showed clinically meaningful improvements.
Full-year 2025 financial guidance reaffirmed; CEO notes base business growing >20% YoY.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.